{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"113"},{"groupId":"BG005","value":"108"},{"groupId":"BG006","value":"259"}],"units":"Participants"}],"groups":[{"description":"Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"BG000","title":"Phase 1: 2 mg Pomalidomide"},{"description":"Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"BG001","title":"Phase 1: 3 mg Pomalidomide"},{"description":"Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"BG002","title":"Phase 1: 4 mg Pomalidomide"},{"description":"Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"BG003","title":"Phase 1: 5 mg Pomalidomide"},{"description":"Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (either 40mg or 20 mg) on days 1, 8, 15, and 22 of each 28-day cycle.","id":"BG004","title":"Phase 2: Pomalidomide + Dexamethasone"},{"description":"4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone at the starting dose in addition to their current dose of pomalidomide, or to discontinue treatment.","id":"BG005","title":"Phase 2: Pomalidomide"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.83","value":"64.7"},{"groupId":"BG001","spread":"6.63","value":"70.4"},{"groupId":"BG002","spread":"8.98","value":"67.5"},{"groupId":"BG003","spread":"14.06","value":"61.3"},{"groupId":"BG004","spread":"9.24","value":"64.4"},{"groupId":"BG005","spread":"10.35","value":"62.9"},{"groupId":"BG006","spread":"9.86","value":"64.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"99"},{"groupId":"BG005","value":"95"},{"groupId":"BG006","value":"226"}]}],"title":"<=75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"33"}]}],"title":">75 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"51"},{"groupId":"BG005","value":"51"},{"groupId":"BG006","value":"122"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"62"},{"groupId":"BG005","value":"57"},{"groupId":"BG006","value":"137"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"7"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"34"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"92"},{"groupId":"BG005","value":"86"},{"groupId":"BG006","value":"213"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"5"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"53"},{"groupId":"BG005","value":"44"},{"groupId":"BG006","value":"110"}]}],"title":"Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"56"},{"groupId":"BG005","value":"59"},{"groupId":"BG006","value":"140"}]}],"title":"Abnormal, not clinically significant"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"}]}],"title":"Abnormal, clinically significant"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"8"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Baseline Electrocardiogram Findings","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"32"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"62"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"68"},{"groupId":"BG005","value":"71"},{"groupId":"BG006","value":"163"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"32"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"}]}],"title":"3"}],"description":"The ECOG scale is as follows:\n\nGrade 0: Fully active, able to carry on all pre-disease activities without restriction; Grade 1: Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours; Grade 3: Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or chair.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"23"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"29"},{"groupId":"BG006","value":"64"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"76"},{"groupId":"BG005","value":"71"},{"groupId":"BG006","value":"172"}]}],"title":"Stage III"}],"description":"Multiple myeloma has three stages, which are known as stage I, stage II and stage III. Staging in myeloma is done on the basis of the value of serum albumin and beta-2 microglobulin level. Stage I has the best prognosis and stage III the worst prognosis.","paramType":"NUMBER","title":"Baseline Multiple Myeloma Stage","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"113"},{"groupId":"BG005","value":"108"},{"groupId":"BG006","value":"259"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior Anti-Myeloma Therapies","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"76"},{"groupId":"BG005","value":"72"},{"groupId":"BG006","value":"178"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"36"},{"groupId":"BG006","value":"81"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior Thalidomide Exposure","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"84"},{"groupId":"BG005","value":"82"},{"groupId":"BG006","value":"191"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"68"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior Stem Cell Transplant","unitOfMeasure":"participants"}],"populationDescription":"Intent to treat population from both phases"}